Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Change in Receivables: 2011-2025

Historic Change in Receivables for Mimedx Group (MDXG) over the last 13 years, with Sep 2025 value amounting to $11.0 million.

  • Mimedx Group's Change in Receivables rose 1055.72% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.8 million, marking a year-over-year increase of 372.35%. This contributed to the annual value of $2.6 million for FY2024, which is 79.15% down from last year.
  • Per Mimedx Group's latest filing, its Change in Receivables stood at $11.0 million for Q3 2025, which was up 51.08% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, Mimedx Group's Change in Receivables ranged from a high of $11.0 million in Q3 2025 and a low of -$4.0 million during Q2 2024.
  • For the 3-year period, Mimedx Group's Change in Receivables averaged around $3.7 million, with its median value being $3.3 million (2024).
  • In the last 5 years, Mimedx Group's Change in Receivables plummeted by 89,200.00% in 2022 and then skyrocketed by 1,055.72% in 2025.
  • Over the past 5 years, Mimedx Group's Change in Receivables (Quarterly) stood at $9.5 million in 2021, then tumbled by 72.21% to $2.6 million in 2022, then soared by 111.13% to $5.6 million in 2023, then crashed by 59.61% to $2.3 million in 2024, then spiked by 1,055.72% to $11.0 million in 2025.
  • Its last three reported values are $11.0 million in Q3 2025, $7.3 million for Q2 2025, and $7.2 million during Q1 2025.